$GLPG

Galapagos and Gilead form binding collaboration on gamgertamig, an autoimmune T cell engager, with Galapagos receiving 50% of Gilead's $1.675B Ouro Medicines acquisition.

Gilead acquires Ouro Medicines for $1.675B upfront, targeting inflammation pipeline expansion. Galapagos NV partners to co-develop lead asset OM336.

Galapagos and Gilead are in advanced partnership talks for a first-in-class T-cell engager for autoimmune diseases, with 50% cost-sharing and €500 million capital freed for Galapagos.

Galapagos and Gilead plan to jointly develop an Ouro T cell engager for autoimmune diseases, splitting acquisition costs while Galapagos leads development and Gilead commercializes, freeing $500M in Galapagos cash.